Announced Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) (FVIIa) in Individuals with Hemophilia A or B with Inhibitors
Presented CB 2679d (FIX) Phase 1/2 Data at the World Federation of Hemophilia 2018 World Congress
Presented Clinical Data on Marzeptacog alfa (activated) and CB 2679d at the Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis
Appointed Grant Blouse, Ph.D., as Vice President of Translational Research
Joined the Russell 2000 Index
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced operating and financial results for the second quarter ending June 30, 2018 and provided a corporate update.
Recent Milestones:
“We are pleased with the positive interim data from our Phase 2/3 study of marzeptacog alfa (activated) in individuals with hemophilia A or B with inhibitors demonstrating a robust reduction in annualized bleed rates. We plan to complete the Phase 2 portion of this Phase 2/3 study by the end of 2018,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “We are continuing our investigation of the antibody findings in Cohort 6 of our CB 2679d Factor IX program while planning for a Phase 2b study in Q4. Our cash balance is strong, and we are well positioned to continue our clinical development programs through multiple clinical and regulatory milestones in 2018 and 2019.”
Upcoming Milestones
Second Quarter 2018 Results and Financial Highlights
About Catalyst Biosciences
Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia.
For more information, please visit www.catalystbiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statement of historical fact, included in this press release regarding our strategy, the potential uses and benefits of Marzeptacog alfa (activated) (MarzAA) and CB 2679d and development plans for these product candidates are forward-looking statements. Examples of such statements include, but are not limited to, the statement that the company is well positioned to continue its clinical development programs through multiple clinical and regulatory milestones in 2018 and 2019, plans to complete the Phase 2 part of the Phase 2/3 trial of MarzAA and the analysis of the antibody observations from Cohort 6 of the Phase 1/2 trial of CB 2679d, and plans for the commencement of a Phase 2b clinical trial of CB 2679d. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements as a result of various important factors, including, but not limited to, the risk that enrollment or results of clinical trials may be delayed and that such trials may not have satisfactory outcomes, that results from the complete Phase 2 portion of the Phase 2/3 trial of MarzAA or from additional testing of CB 2679d will not replicate interim results or the results from earlier human trials or from prior animal studies, that the analysis of the antibody observations from Cohort 6 of the Phase 1/2 trial of CB 2679d will indicate that development of this product candidate should be halted, that potential adverse effects may arise from the testing or use of MarzAA or CB 2679d, including the generation of additional neutralizing antibodies, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, competition and other factors that affect our ability to establish collaborations on commercially reasonable terms and other risks described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 19, 2018, as updated in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, along with our other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
Contacts:
Investors:
Fletcher Payne, CFO
Catalyst Biosciences, Inc.
1.650.871.0761
investors@catbio.com
Media:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
1.646.751.4361
jo@lifescipublicrelations.com
| Catalyst Biosciences, Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (In thousands, except share and per share amounts) | ||||||||
| June 30, 2018 | December 31, 2017 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 46,533 | $ | 14,472 | ||||
| Short-term investments | 89,613 | 17,971 | ||||||
| Restricted cash | 175 | 5,333 | ||||||
| Prepaid and other current assets | 2,656 | 1,333 | ||||||
| Total current assets | 138,977 | 39,109 | ||||||
| Other assets, noncurrent | 274 | 128 | ||||||
| Property and equipment, net | 291 | 276 | ||||||
| Total assets | $ | 139,542 | $ | 39,513 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 134 | $ | 747 | ||||
| Accrued compensation | 897 | 1,366 | ||||||
| Other accrued liabilities | 1,398 | 1,322 | ||||||
| Deferred revenue | — | 212 | ||||||
| Deferred rent, current portion | 10 | 7 | ||||||
| Redeemable convertible notes | — | 5,085 | ||||||
| Total current liabilities | 2,439 | 8,739 | ||||||
| Deferred rent, noncurrent portion | 140 | — | ||||||
| Total liabilities | 2,579 | 8,739 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized; 0 and 3,680 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively | — | — | ||||||
| Common stock, $0.001 par value, 100,000,000 shares authorized; 11,942,729 and 6,081,230 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively | 12 | 6 | ||||||
| Additional paid-in capital | 321,758 | 204,262 | ||||||
| Accumulated other comprehensive income | 4 | — | ||||||
| Accumulated deficit | (184,811 | ) | (173,494 | ) | ||||
| Total stockholders’ equity | 136,963 | 30,774 | ||||||
| Total liabilities and stockholders’ equity | $ | 139,542 | $ | 39,513 | ||||
| Catalyst Biosciences, Inc. | ||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Contract revenue | $ | — | $ | 111 | $ | 6 | $ | 382 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 3,889 | 3,401 | 7,660 | 5,481 | ||||||||||||
| General and administrative | 3,225 | 2,654 | 6,139 | 5,017 | ||||||||||||
| Total operating expenses | 7,114 | 6,055 | 13,799 | 10,498 | ||||||||||||
| Loss from operations | (7,114 | ) | (5,944 | ) | (13,793 | ) | (10,116 | ) | ||||||||
| Interest and other income, net | 632 | 67 | 2,269 | 101 | ||||||||||||
| Net loss | $ | (6,482 | ) | $ | (5,877 | ) | (11,524 | ) | (10,015 | ) | ||||||
| Deemed dividend for convertible preferred stock beneficial conversion feature | — | (3,951 | ) | — | (3,951 | ) | ||||||||||
| Net loss attributable to common stockholders | $ | (6,482 | ) | $ | (9,828 | ) | $ | (11,524 | ) | $ | (13,966 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.54 | ) | $ | (2.53 | ) | $ | (1.10 | ) | $ | (5.82 | ) | ||||
| Shares used to compute net loss per share attributable to common stockholders, basic and diluted | 11,938,401 | 3,877,736 | 10,472,180 | 2,400,101 | ||||||||||||